RU2022109286A - Кристаллическая форма гидрата свободного основания лорлатиниба - Google Patents
Кристаллическая форма гидрата свободного основания лорлатиниба Download PDFInfo
- Publication number
- RU2022109286A RU2022109286A RU2022109286A RU2022109286A RU2022109286A RU 2022109286 A RU2022109286 A RU 2022109286A RU 2022109286 A RU2022109286 A RU 2022109286A RU 2022109286 A RU2022109286 A RU 2022109286A RU 2022109286 A RU2022109286 A RU 2022109286A
- Authority
- RU
- Russia
- Prior art keywords
- ppm
- crystalline form
- free base
- base hydrate
- cancer
- Prior art date
Links
- 239000012458 free base Substances 0.000 title claims 11
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 title claims 11
- 229950001290 lorlatinib Drugs 0.000 title claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 5
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 3
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 3
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 claims 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 108700020796 Oncogene Proteins 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- -1 hydrate pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-3-carbonitrile Chemical compound 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570326P | 2017-10-10 | 2017-10-10 | |
| US62/570,326 | 2017-10-10 | ||
| US201862727734P | 2018-09-06 | 2018-09-06 | |
| US62/727,734 | 2018-09-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020113141A Division RU2845218C2 (ru) | 2017-10-10 | 2018-10-04 | Кристаллическая форма гидрата свободного основания лорлатиниба |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2022109286A true RU2022109286A (ru) | 2022-05-06 |
Family
ID=64049474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2022109286A RU2022109286A (ru) | 2017-10-10 | 2018-10-04 | Кристаллическая форма гидрата свободного основания лорлатиниба |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11299500B2 (enExample) |
| EP (1) | EP3694863B1 (enExample) |
| JP (1) | JP7153069B2 (enExample) |
| KR (1) | KR102424621B1 (enExample) |
| CN (1) | CN111201235B (enExample) |
| AU (1) | AU2018349259B2 (enExample) |
| CA (1) | CA3077508C (enExample) |
| CY (1) | CY1126141T1 (enExample) |
| DK (1) | DK3694863T3 (enExample) |
| ES (1) | ES2952985T3 (enExample) |
| FI (1) | FI3694863T3 (enExample) |
| HU (1) | HUE062926T2 (enExample) |
| MX (1) | MX2020003373A (enExample) |
| PL (1) | PL3694863T3 (enExample) |
| PT (1) | PT3694863T (enExample) |
| RU (1) | RU2022109286A (enExample) |
| SG (1) | SG11202002445SA (enExample) |
| SI (1) | SI3694863T1 (enExample) |
| TW (1) | TWI775960B (enExample) |
| WO (1) | WO2019073347A1 (enExample) |
| ZA (1) | ZA202001661B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3328867T3 (da) | 2015-07-31 | 2020-11-16 | Pfizer | Krystallinsk form af fri base af lorlatinib |
| EP3770164A1 (en) | 2016-04-08 | 2021-01-27 | Pfizer Inc | Crystalline forms of lorlatinib maleate |
| WO2019209633A1 (en) * | 2018-04-23 | 2019-10-31 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| WO2021011345A1 (en) * | 2019-07-18 | 2021-01-21 | Pliva Hrvatska D.O.O | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| CN111362967B (zh) * | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| JP5808818B2 (ja) * | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| US9422226B2 (en) | 2011-06-08 | 2016-08-23 | Biogen Ma Inc. | Process for preparing high purity and crystalline dimethyl fumarate |
| GEP201606560B (en) | 2012-03-06 | 2016-10-25 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| CA2916605C (en) * | 2013-06-28 | 2018-04-24 | Pfizer Inc. | Solid forms of a macrocyclic kinase inhibitor |
| JP6609308B2 (ja) * | 2014-08-20 | 2019-11-20 | テリジーン リミテッド | キナーゼ阻害剤としての置換マクロサイクル |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| DK3328867T3 (da) * | 2015-07-31 | 2020-11-16 | Pfizer | Krystallinsk form af fri base af lorlatinib |
| EP3770164A1 (en) | 2016-04-08 | 2021-01-27 | Pfizer Inc | Crystalline forms of lorlatinib maleate |
-
2018
- 2018-10-04 CN CN201880065709.6A patent/CN111201235B/zh active Active
- 2018-10-04 KR KR1020207010512A patent/KR102424621B1/ko active Active
- 2018-10-04 PL PL18795807.9T patent/PL3694863T3/pl unknown
- 2018-10-04 EP EP18795807.9A patent/EP3694863B1/en active Active
- 2018-10-04 JP JP2020520115A patent/JP7153069B2/ja active Active
- 2018-10-04 WO PCT/IB2018/057735 patent/WO2019073347A1/en not_active Ceased
- 2018-10-04 AU AU2018349259A patent/AU2018349259B2/en active Active
- 2018-10-04 CA CA3077508A patent/CA3077508C/en active Active
- 2018-10-04 MX MX2020003373A patent/MX2020003373A/es unknown
- 2018-10-04 FI FIEP18795807.9T patent/FI3694863T3/fi active
- 2018-10-04 HU HUE18795807A patent/HUE062926T2/hu unknown
- 2018-10-04 US US16/650,505 patent/US11299500B2/en active Active
- 2018-10-04 RU RU2022109286A patent/RU2022109286A/ru unknown
- 2018-10-04 SG SG11202002445SA patent/SG11202002445SA/en unknown
- 2018-10-04 ES ES18795807T patent/ES2952985T3/es active Active
- 2018-10-04 DK DK18795807.9T patent/DK3694863T3/da active
- 2018-10-04 PT PT187958079T patent/PT3694863T/pt unknown
- 2018-10-04 SI SI201830952T patent/SI3694863T1/sl unknown
- 2018-10-05 TW TW107135186A patent/TWI775960B/zh active
-
2020
- 2020-03-17 ZA ZA2020/01661A patent/ZA202001661B/en unknown
-
2023
- 2023-07-25 CY CY20231100357T patent/CY1126141T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI3694863T3 (fi) | 2023-08-18 |
| ES2952985T3 (es) | 2023-11-07 |
| EP3694863A1 (en) | 2020-08-19 |
| CA3077508C (en) | 2023-02-14 |
| HUE062926T2 (hu) | 2023-12-28 |
| WO2019073347A1 (en) | 2019-04-18 |
| TW201922753A (zh) | 2019-06-16 |
| CA3077508A1 (en) | 2019-04-18 |
| AU2018349259A1 (en) | 2020-04-09 |
| PL3694863T3 (pl) | 2023-09-25 |
| PT3694863T (pt) | 2023-08-23 |
| AU2018349259B2 (en) | 2021-02-18 |
| RU2020113141A3 (enExample) | 2021-11-12 |
| SI3694863T1 (sl) | 2023-10-30 |
| MX2020003373A (es) | 2020-10-12 |
| EP3694863B1 (en) | 2023-06-21 |
| CY1126141T1 (el) | 2023-11-15 |
| TWI775960B (zh) | 2022-09-01 |
| DK3694863T3 (da) | 2023-07-03 |
| US20200308191A1 (en) | 2020-10-01 |
| SG11202002445SA (en) | 2020-04-29 |
| JP2020536893A (ja) | 2020-12-17 |
| US11299500B2 (en) | 2022-04-12 |
| RU2020113141A (ru) | 2021-11-12 |
| JP7153069B2 (ja) | 2022-10-13 |
| CN111201235B (zh) | 2023-02-10 |
| BR112020005989A2 (pt) | 2020-09-29 |
| KR102424621B1 (ko) | 2022-07-25 |
| KR20200051781A (ko) | 2020-05-13 |
| ZA202001661B (en) | 2023-11-29 |
| CN111201235A (zh) | 2020-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2022109286A (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| JP2020536893A5 (enExample) | ||
| RU2018101363A (ru) | Кристаллическая форма свободного основания лорлатиниба | |
| AU2018209667B2 (en) | JAK1 selective inhibitors | |
| EP2788351B1 (en) | SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASE INHIBITORS | |
| JP6563623B1 (ja) | ピリドピリミジノンｃｄｋ２／４／６阻害剤 | |
| ES2958948T3 (es) | Derivados de 2,3-dihidro-1H-pirrolo[3,4-c]piridin-1-ona como inhibidores de HPK1 para el tratamiento del cáncer | |
| JP5925394B2 (ja) | 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体 | |
| ES2816600T3 (es) | Sal tosilato de (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-il)-8,9-dihidro-2H-pirido[4,3,2-de]ftalazin-3(7H)-ona cristalina | |
| CN111770914B (zh) | 作为神经激肽-1受体拮抗剂的化合物及其用途 | |
| CA3085590A1 (en) | Substituted indole compounds useful as tlr inhibitors | |
| CN120077048A (zh) | 三环化合物及其用途 | |
| JP2017039702A5 (enExample) | ||
| RU2012138892A (ru) | СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5,-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА | |
| KR20230027275A (ko) | Hiv 치료용 캡시드 저해제 | |
| AU2019218186B2 (en) | Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof | |
| CA3011880A1 (en) | Substituted cyanoindoline derivatives as nik inhibitors | |
| WO2020052627A1 (zh) | 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途 | |
| WO2018197653A9 (en) | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production | |
| WO2023059609A1 (en) | Heterobifunctional compounds and their use in treating disease | |
| WO2017031427A1 (en) | COMPOUNDS AND METHODS FOR INHIBITING mTOR | |
| EP4313969A1 (en) | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | |
| JP2015522037A5 (enExample) | ||
| TW202027750A (zh) | 治療癌症之套組及其方法 | |
| CA3059455A1 (en) | Compound of eoc315 mod.i crystal form and preparation method therefor |